<?xml version="1.0" ?>
<GlossaryTerm id="CDR0000390321">
  <TermName>vatalanib</TermName>
  <TermPronunciation>(va-TAH-la-nib)</TermPronunciation>
  <TermDefinition>
    <DefinitionText>A substance that is being studied in the treatment of cancer. It belongs to the families of drugs called protein tyrosine kinase inhibitors and VEGF receptor kinase inhibitors. Also called PTK787/ZK 222584.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </TermDefinition>
  <MediaLink ref="CDR0000713072" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;vatalanib&quot;" language="en" id="_3"/>
  <MediaLink ref="CDR0000713071" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;vatalanib&quot;" language="es" id="_4"/>
  <SpanishTermName>vatalanib</SpanishTermName>
  <SpanishTermDefinition>
    <DefinitionText>Sustancia en estudio para el tratamiento del cáncer. Pertenece a la familia de medicamentos conocidos como inhibidores de proteinas tirosina–cinasas e inhibidores de la cinasa del receptor del VEGF. También se llama PTK787/ZK 222584.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </SpanishTermDefinition>
  <DateFirstPublished>2004-10-25</DateFirstPublished>
  <DateLastModified>2004-10-21</DateLastModified>
</GlossaryTerm>
